Evidence justifies clinical research on NSAIDs for PCa
The presentations of Jay Pearson, PhD, and Brett Carver, MD, cited in this issue of Urology Times, provide further experimental and epidemiologic evidence that nonsteroidal anti-inflammatory drugs (NSAIDs) may have some role in the fight against prostate cancer. While these are certainly not the first reports that NSAIDs might beuseful for the prevention or treatment of this malignancy, they continueto identify the remarkable value of these agents for human health and raiseimportant questions as to why so many different types of disease statesare affected by them. Arthritis, benign cardiac conditions, and colon andprostate cancer are diseases of extraordinarily different tissues, etiologies,pathologies, and outcomes. Yet each of these conditions are likely benefitedby NSAID therapy.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.
Justin B. Ziemba, MD, discusses clinical factors that help identify patients at increased risk for kidney stone recurrence and guide metabolic evaluation.
Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.